Advances in immunotherapy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy with checkpoint inhibitors has shown strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangro, Bruno, Sarobe, Pablo, Hervás-Stubbs, Sandra, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042636/
https://www.ncbi.nlm.nih.gov/pubmed/33850328
http://dx.doi.org/10.1038/s41575-021-00438-0

Ejemplares similares

Ejemplares similares